Sector News

Roche to buy Flatiron Health for $1.9 billion

February 16, 2018
Life sciences

Swiss drugmaker Roche Holding AG said on Thursday it would buy the rest of U.S. cancer data company Flatiron Health for $1.9 billion to speed development of cancer medicines and support its efforts to price them based on how well they work.

Privately held Flatiron, backed by Alphabet Inc, taps into data on individual cancer cases to help doctors select promising approaches for their patients.

It also stores billing data, doctors’ notes and related information.

Roche currently owns 12.6 percent of Flatiron.

In 2016, Roche led a $175 million investment into Flatiron, in part to help the Swiss company harness the deluge of still-underutilized data collected from cancer patients with the New York City-based company’s products.

Roche has said Flatiron algorithms will improve not only its research and trials, but also buttress its arguments during head-to-head price talks with payers as new combinations of its expensive therapies hit the market.

“It gives us better insights into the potential for our products,” Roche’s head of pricing Jens Grueger told Reuters in a 2016 interview.

“But it also creates flexibility in how we can create value contracts in the future.”

Roche has made a number of bolt-on acquisitions in recent months, including in December when it said it would buy U.S. cancer drug specialist Ignyta Inc for $1.7 billion in a deal to broaden its oncology portfolio.

In 2014, Google Ventures led a $130 million investment in Flatiron as healthcare had become a hot area for venture capital, especially companies related to health, data and software.

Roche and Flatiron expect the deal to close in the first half of 2018, after which the latter will continue its operations as a separate entity.

Allen & Company LLC is the financial adviser to Flatiron Health and Wilson Sonsini Goodrich & Rosati is its legal counsel. Davis Polk & Wardwell LLP is acting as legal counsel to Roche.

By Akankshita Mukhopadhyay and John Miller

Source: Reuters

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.